Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline.

LONDON, May 12, 2026 /PRNewswire/ -- Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $2.1 Billion in Series B funding. This latest round of investment will accelerate the company's evolution from pioneering novel AI models to applying them at scale.

The financing round is led by Thrive Capital, and includes participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, significantly expanding Isomorphic Labs' global capital base.

The new capital will be used for the continued development and deployment of Isomorphic Labs' AI drug design engine (IsoDDE), accelerating and expanding its pipeline of therapeutic programs towards the clinic. Additionally, the funding will support our existing hiring targets by integrating world-class AI, engineering, drug design, and clinical talent across our sites; this global scale is crucial to Isomorphic Labs' long-term vision of applying AI-driven breakthroughs to the most complex biological and medical challenges and addressing the global burden of disease.

This funding round serves as further validation of the progress of Isomorphic Labs' AI drug design capabilities and marks a pivotal moment for the company, demonstrating that its first-principles approach positions it to define the future of AI-driven drug design. By reimagining drug discovery as an integrated scientific and engineering discipline with proprietary AI and data at the core, Isomorphic Labs aims to deliver scientific breakthroughs with a level of precision and speed previously thought impossible.

"The application of AI in healthcare offers a profound opportunity. Isomorphic Labs has already made extraordinary progress in harnessing AI to accelerate drug discovery, and we are excited by this momentum and the early promise of the technology platform," said Ruth Porat, President and Chief Investment Officer Alphabet and Google. "This trajectory is encouraging, and this funding will be used to accelerate the work and bring important interventions to market with greater speed."

"This funding round is a massive vote of confidence from a diverse group of top-tier international investors in our AI-first approach to drug design and development," said Sir Demis Hassabis, Founder and CEO. "Now that we have shown our approach is fundamentally sound, our focus is on scaling our technology to its full potential. This capital injection allows us to build out our drug design engine at scale, driving us forward in our mission to solve all disease."

"This milestone is built on the strength of our AI drug design engine, which has already proven its worth across our internal programs by hitting key milestones and identifying viable candidates with unprecedented speed," said Max Jaderberg, President of Isomorphic Labs. "Our drug design engine works, and it's giving us a repeatable way to design new medicines for a wide range of diseases, building a future of medicine that was previously out of reach."

"We are humbled to have the opportunity to continue to support Isomorphic's mission to solve all disease," said Joshua Kushner, Founder and CEO of Thrive Capital. "Over the past year, our conviction in the team has only deepened as they've made significant progress in building a unified AI drug design engine to define a new age of drug discovery and design."

"The caliber of the team Isomorphic has assembled is unmatched, and they continue to validate our belief that this is the premier group at the intersection of AI and drug discovery," said Dr. Krishna Yeshwant, Managing Partner at GV. "We have strong confidence in Isomorphic. We believe their approach can create important medicines that will be better understood earlier in the process, pushing the boundaries of what's been possible before."

Technical Advancement and Strategic Impact

Isomorphic Labs has developed a number of proprietary breakthrough AI models that together form its unified AI drug design engine that works across multiple therapeutic areas and drug modalities. Isomorphic Labs recently published a subset of the powerful and expansive capabilities of IsoDDE, highlighting its predictive accuracy and introducing new capabilities which bridge the gap between structure prediction and real-world drug discovery. IsoDDE offers a scalable foundation for AI drug design, providing the predictive fidelity required to navigate novel biological systems with unprecedented accuracy.

Isomorphic Labs maintains a strong portfolio of strategic partnerships with industry leaders like Novartis, Lilly, and Johnson & Johnson. These collaborations serve as a significant validation of Isomorphic's AI-first approach and the tangible value it brings to the pharmaceutical industry.

ABOUT ISOMORPHIC LABS

Isomorphic Labs was founded in 2021, to transform drug discovery with the power of artificial intelligence, ushering in a new era of biomedical breakthroughs. Isomorphic Labs is led by CEO Sir Demis Hassabis and President Max Jaderberg. Isomorphic Labs has built a world-leading AI drug design engine comprising foundational AI models that are capable of working across multiple therapeutic areas and drug modalities. The company is continually innovating on model architecture and developing cutting-edge capabilities to advance drug design. Isomorphic Labs is headquartered in London and has office locations in Cambridge, Massachusetts and Lausanne, Switzerland. Isomorphic Labs is advancing a broad and ambitious drug design portfolio through partnered programs and wholly-owned internal programs. For more information, go to www.isomorphiclabs.com and follow us on LinkedIn and X.

For Media Inquiries

press@isomorphiclabs.com

View original content:https://www.prnewswire.co.uk/news-releases/isomorphic-labs-secures-2-1-billion-funding-to-scale-its-ai-drug-design-engine-302769702.html

Der US-Datenkonzern Palantir hat in der Schweiz eine deutliche juristische Niederlage erlitten. Das Handelsgericht Zürich wies 22 von 23 beanstandeten Passagen in zwei kritischen Artikeln des Online-Magazins «Republik» zurück. Lediglich eine einzelne Formulierung muss die Redaktion korrigieren. Palantir und seine Schweizer Tochtergesellschaft wollten gerichtlich durchsetzen, dass umfangreiche Gegendarstellungen publiziert werden; dieses Anliegen ist nun weitgehend gescheitert. Nach dem Urteil muss der Konzern zudem den überwiegenden Teil der Verfahrenskosten tragen.

Ausgangspunkt des Rechtsstreits waren Recherchen, die im Dezember 2025 nach rund einjähriger Arbeit erschienen. Das Projekt von «Republik» und dem Recherchekollektiv WAV beleuchtete, wie Palantir über mehrere Jahre versucht hatte, bei Bundesstellen und dem Schweizer Militär Aufträge zu erhalten – ohne Erfolg. Die Journalisten werteten dazu Dutzende Gesuche nach dem Öffentlichkeitsgesetz sowie interne Unterlagen aus und kamen zum Befund, dass das Unternehmen trotz einer mehrjährigen Präsenz in der Schweiz keinen einzigen Regierungsauftrag gewinnen konnte. Diese Erzählung eines «Scheiterns» auf dem Schweizer Markt war nach Darstellung der beteiligten Reporter Auslöser für Palantirs juristische Offensive.

Die Redaktion hatte dem Unternehmen nach eigenen Angaben vor Veröffentlichung ausführliche Fragen geschickt und Führungskräfte interviewt. Palantir verlangte darüber hinaus eine detaillierte, punktweise Replik im Magazin, die über den Umfang der ursprünglichen Recherche hinausgegangen wäre. Als «Republik» dies ablehnte, reichte der Konzern Klage ein. Das Zürcher Handelsgericht stellte nun klar, dass nur eine von 23 umstrittenen Passagen eine Gegendarstellung erfordert. Damit bestätigt das Urteil, dass der Großteil der Berichterstattung über Palantirs vergebliche Akquisitionsversuche bei Schweizer Behörden auf einer zulässigen Auswertung amtlicher Dokumente beruht.

Palantir ist international vor allem durch den Einsatz seiner Software in militärischen und nachrichtendienstlichen Kontexten bekannt. Seit 2022 stellt das Unternehmen Plattformen zur Verfügung, die ukrainische Behörden und Streitkräfte bei der Auswertung von Lagebildern, der Zielidentifikation und der Logistik unterstützen. Die Systeme werden außerdem von US-amerikanischen und verbündeten Diensten im Nahen Osten genutzt, um iranische Aktivitäten etwa in Raketenprogrammen, beim Einsatz von Drohnen oder in Cyberoperationen zu analysieren. Direkte Geschäftsbeziehungen mit dem Iran bestehen nach Unternehmensangaben aufgrund von US-Sanktionen nicht. Das Zürcher Urteil könnte über die Schweiz hinaus Signalwirkung haben, nachdem die Recherche bereits in anderen europäischen Staaten Debatten über Nutzen und Notwendigkeit der Palantir-Technologie im staatlichen Bereich angestoßen hatte.